Adropin and Irisin in Patients with Cardiac Cachexia

Kalkan, Ali Kemal; Çakmak, Hüseyin Altuğ; Ertürk, Mehmet; Kalkan, Kübra Erol; Uzun, Fatih; Taşbulak, Ömer; Diker, Vesile Ornek; Aydın, Süleyman; Çelik, Ahmet

doi:10.5935/abc.20180109

Cited by 22 publications

(28 citation statements)

References 41 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In partial agreement with our results, Kalkan et al 2018 Our study measured the cardiac biomarkers (cardiac CK-MB and troponin-I) which were significantly elevated in both groups of patients compared to the control group. This is in accordance with Aydin et al 2014a;Kuloglu et al 2014;Yilmaz et al 2006 who demonstrated a relationship between clinical severity of the disease and elevation of myocardial enzymes (CK-MB and troponin I).…”

Section: Discussionsupporting

confidence: 92%

Serum irisin level in myocardial infarction patients with or without heart failure

El-Mottaleb

Galal

Maghraby

et al. 2019

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

This study aimed to assess serum irisin level in myocardial infarction (MI) with or without heart failure (HF) and the possible relation between irisin and cardiac markers, TNF-α and lipid profile. 86 subjects were included (33 patients had MI, 33 patients had MI with HF and 20 controls). Body Mass Index (BMI), waist/hip ratio (WHR), systolic and diastolic blood pressure (SBP and DBP), heart rate, left ventricular ejection fraction (LVEF) were measured. Blood samples were withdrawn on admission for measuring irisin, cardiac markers, TNF-α, total cholesterol (TC), triglycerides (TGs), low density lipoprotein-cholesterol concentration (LDL-C) and high-density lipoprotein-cholesterol concentration (HDL-C). Patients with MI and HF had reduced serum irisin, LVEF and HDL-C and higher levels of BMI, WHR, SBP, DBP, troponin-I, CK-MB, TNF-α, TC, TGs and LDL-C compared to control. Negative correlations were observed between irisin and BMI, WHR, SBP, DBP, troponin-I, CK-MB, TNF-α, TC, TGs and LDL-C. However, positive association was noticed between irisin and LVEF and HDL-C. Irisin might be a useful biomarker in diagnosis of MI with or without HF. It could have antiinflammatory and hypolipidemic effects. Further studies are needed to elucidate the role of irisin as a promising prophylactic or therapeutic agent in cardiovascular diseases.

show abstract

Section: Discussionsupporting

confidence: 92%

Serum irisin level in myocardial infarction patients with or without heart failure

El-Mottaleb

Galal

Maghraby

et al. 2019

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Firstly known as a molecule responsible for the browning of WAT (Giralt and Villarroya, 2013), it was also shown that its levels strongly increase after resistance exercise (Miyamoto-Mikami et al, 2015; Zhao et al, 2017), but not in aerobic training (Kim et al, 2016). Moreover, it was also recently proposed as a novel marker for patients with cardiac cachexia (Kalkan et al, 2018). Even if it was shown that it can mediate those beneficial effects that follow exercise (inducing the expression of pro-myogenic genes in myotubes), its role in physical activity still remain controversial.…”

Section: Myokines and The Contracting Musclementioning

confidence: 99%

Extracellular Vesicles: Delivery Vehicles of Myokines

2019

View full text Add to dashboard Cite

Movement and regular physical activity are two important factors that help the human body prevent, reduce and treat different chronic diseases such as obesity, type 2 diabetes, heart diseases, hypertension, sarcopenia, cachexia and cancer. During exercise, several tissues release molecules into the blood stream, and are able to mediate beneficial effects throughout the whole body. In particular, contracting skeletal muscle cells have the capacity to communicate with other organs through the release of humoral factors that play an important role in the mechanisms of adaptation to physical exercise. These muscle-derived factors, today recognized as myokines, act as endocrine and paracrine hormones. Moreover, exercise may stimulate the release of small membranous vesicles into circulation, whose composition is influenced by the same exercise. Combining the two hypotheses, these molecules related to exercise, named exer-kines, might be secreted from muscle cells inside small vesicles (nanovesicles). These could act as messengers in tissue cross talk during physical exercise. Thanks to their ability to deliver useful molecules (such as proteins and miRNA) in both physiological and pathological conditions, extracellular vesicles can be thought of as promising candidates for potential therapeutic and diagnostic applications for several diseases.

show abstract

“…First, we noted significantly lower level of circulating irisin in cachectic CHF patients compared to non-cachectic study participants (median: 7.12 µg/mL vs. 7.61 µg/mL; p = 0.022). This result is different from that reported by Kalkan et al [5]. The reason for this might be the group of patients (our group consisted only of women, whereas the a above-mentioned study included both women and men), different criteria for the cachexia assessment (in our research we used the ones proposed by Evans et al [15] whereas in Kalkan study the ones applied by [17,18]).…”

Section: Discussionmentioning

confidence: 59%

“…Cachectic patients (n = 44, mean age: 65.4 ± 11.2; 61.4% men) were identified in the study group of 86 patients. Serum irisin level was significantly higher in the cachexia group than in the controls (Irisin (µg/mL); 2.6 (IQR:2.2-4.4) vs. 2.1 (IQR:1.8-2.4); p = 0.001), and positively correlated with BNP levels and NYHA class, and negatively correlated with BMI and serum albumin level (all p values: <0.001) [5]. The results suggest that adropin and irisin may be novel markers of cardiac cachexia in patients with heart failure with a reduced ejection fraction.…”

Section: Discussionmentioning

confidence: 88%

“…Due to metabolic alterations associated with the disease, CHF patients are increasingly diagnosed with heart failure-induced cachexia (cardiac cachexia; CC), which is diagnosed in 8-42% CHF patients, and the mortality rate is roughly 20-30%. Progression of cachexia in CHF patients is based on the reduced myocardial perfusion, cardiomyocyte decline and the depletion of high energy stores (reduced cardiac function and increased catabolic state of the body) [3][4][5]. Until now, there is lack of literature reports concerning combined use of hormonal markers (e.g., irisin) and other tools (bioelectrical impedance analysis, BIA) in the management of cachexia in patients with CHF.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Electrical and Hormonal Biomarkers in Cachectic Elderly Women with Chronic Heart Failure

Sobieszek

Powrózek

Mazurek

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Cachexia is an unfavorable metabolic syndrome causing involuntary weight loss followed by muscle wasting, which can lead to the exacerbation of chronic heart failure (CHF), and considerably increases mortality rate among CHF patients. Unfortunately, until now it has not been possible to determine factors that could improve clinical options for cachexia management or enable the identification of patients at risk of its development. We assessed how cachexia conditions in CHF reflect cardiac and laboratory parameters in comparison with non-cachectic patients. Methods: 66 women were enrolled to the study group and underwent meticulous screening, according to recent clinical guidelines, in order to enable CHF and cachexia detection. Body composition was evaluated by bioelectrical impedance analysis (BIA) and laboratory tests were supplemented by analysis of plasma circulating irisin. Results: A negative correlation between irisin concentration and both CRP and TNF-α was recorded (R = −0.362 and R = −0.243; p < 0.05). Irisin concentration positively correlated with EF% (R = 0.253; p = 0.046) and negatively with LVESd, LVEDd and NT-proBNP (R = −0.326, −0.272, and −0.320; p < 0.05). Both low levels of circulating irisin and Capacitance of membrane (Cm) were selected as unfavorable factors affecting cachexia in CHF patients (OR = 1.39 and 34.49; p < 0.05). Combination of Cm, irisin, CRP and albumin demonstrated sensitivity of 93.3% and specificity of 85.3% (AUC = 0.949) for distinguishing between cachectic and non-cachectic CHF patients. Conclusions: Selected parameters reliably reflect cachectic conditions in CHF, and the proposed approach for cachexia based on the combined analysis of at least a few non-invasive markers could offer new opportunities for improving clinical outcomes in CHF patients.

show abstract

Adropin and Irisin in Patients with Cardiac Cachexia

Cited by 22 publications

References 41 publications

Serum irisin level in myocardial infarction patients with or without heart failure

Serum irisin level in myocardial infarction patients with or without heart failure

Extracellular Vesicles: Delivery Vehicles of Myokines

Electrical and Hormonal Biomarkers in Cachectic Elderly Women with Chronic Heart Failure

Contact Info

Product

Resources

About